Key result
Danhong injection significantly attenuated doxorubicin-induced cardiotoxicity in rats by preventing weight loss, improving ECG performance, reducing serum injury markers, and suppressing apoptosis.
Why the study?
The clinical use of doxorubicin is limited by its cardiotoxicity, prompting evaluation of the potential protective effects and underlying mechanisms of Danhong injection.
Does Danhong injection prevent doxorubicin-induced cardiotoxicity in a rat model?
Population
DOX-induced chronic cardiotoxicity rat model and DOX-treated H9c2 cells
Comparison
Danhong injection vs DOX alone
Design
Preclinical animal and in vitro laboratory study with network pharmacology analysis
Authors
Loading...
DHI attenuates DOX cardiotoxicity via apoptosis suppression in rats; leaves open translation to human cardio-oncology.
Does Danhong injection prevent doxorubicin-induced cardiotoxicity in a rat model?
p-value: p=<0.05
Danhong injection attenuates doxorubicin-induced cardiotoxicity in rats by suppressing the apoptosis pathway, suggesting its potential as a cardioprotective agent in cardio-oncology.
Yi et al. (2022) studied Doxorubicin-induced cardiotoxicity (n=40). Danhong injection vs. Doxorubicin alone (2.5 mg/kg intraperitoneally every other day) was evaluated on Cardiotoxicity (body weight, heart weight, ECG, serum biochemical indicators, oxidative stress, and apoptosis) (p=<0.05). Danhong injection significantly attenuated doxorubicin-induced cardiotoxicity in rats by preventing weight loss, improving ECG performance, reducing serum injury markers, and suppressing apoptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: